Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody.

Zhang ZL, Zhang JF, Yuan YF, He YM, Liu QY, Mao XW, Ai YB, Liu ZS.

Exp Ther Med. 2014 Mar;7(3):543-552. Epub 2014 Jan 7.

2.
3.

Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.

Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, Nose A, Iba O, Tateishi E, Ogata N, Jyo N, Higashiyama S, Iwasaka T.

Circ Res. 2001 Jan 19;88(1):22-9. Retraction in: Circ Res. 2013 Jun 7;112(12):e180.

4.

The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization.

Zeng W, Gouw AS, van den Heuvel MC, Zwiers PJ, Zondervan PE, Poppema S, Zhang N, Platteel I, de Jong KP, Molema G.

Hepatology. 2008 Nov;48(5):1517-27. doi: 10.1002/hep.22490.

PMID:
18924243
5.

Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.

Hosseini H, Rajabibazl M, Ebrahimizadeh W, Dehbidi GR.

Microvasc Res. 2015 Jan;97:13-8. doi: 10.1016/j.mvr.2014.09.002. Epub 2014 Sep 22.

PMID:
25250517
6.

T7 peptide inhibits angiogenesis via downregulation of angiopoietin-2 and autophagy.

Wang F, Dong X, Xiu P, Zhong J, Wei H, Xu Z, Li T, Liu F, Sun X, Li J.

Oncol Rep. 2015 Feb;33(2):675-84. doi: 10.3892/or.2014.3653. Epub 2014 Dec 5.

PMID:
25483829
7.
8.

Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.

Hu C, Li W, Tian F, Jiang K, Liu X, Cen J, He Q, Qiu Z, Kienast Y, Wang Z, Zhang H, Ji Y, Hu J, Hui L.

J Hepatol. 2017 Nov 4. pii: S0168-8278(17)32409-1. doi: 10.1016/j.jhep.2017.10.028. [Epub ahead of print]

PMID:
29113912
9.

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.

Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J, Brinkmann U, Weidner KM, Regula J, Klein C.

MAbs. 2016;8(3):562-73. doi: 10.1080/19420862.2016.1147640.

10.

Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.

Wada H, Nagano H, Yamamoto H, Arai I, Ota H, Nakamura M, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Doki Y, Dono K, Nakamori S, Sakon M, Monden M.

Oncol Rep. 2007 Oct;18(4):801-9.

PMID:
17786339
11.

Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?

Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY, Tarnawski AS.

Mod Pathol. 2003 Jun;16(6):552-7.

12.

Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma.

Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F, Yoshidome H, Kato A, Nukui Y, Miyazaki M.

Hepatology. 2003 May;37(5):1105-13.

PMID:
12717391
13.

Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma.

Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR.

J Clin Invest. 1999 Feb;103(3):341-5.

15.

Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo.

Suzuki R, Yamamoto H, Ngan CY, Ohtsuka M, Kitani K, Uemura M, Nishimura J, Takemasa I, Mizushima T, Sekimoto M, Minamoto T, Doki Y, Mori M.

Int J Oncol. 2013 Nov;43(5):1447-55. doi: 10.3892/ijo.2013.2076. Epub 2013 Aug 23.

PMID:
23982687
16.

IL-35 Inhibits Angiogenesis through VEGF/Ang2/Tie2 Pathway in Rheumatoid Arthritis.

Jiang S, Li Y, Lin T, Yuan L, Li Y, Wu S, Xia L, Shen H, Lu J.

Cell Physiol Biochem. 2016;40(5):1105-1116. Epub 2016 Dec 14.

17.

Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice.

Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Uemura M, Masaki T, Fukui H.

Gut. 2005 Dec;54(12):1768-75. Epub 2005 Jul 20.

18.

Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors.

Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD, Ellis LM.

Cancer Res. 2003 Jun 15;63(12):3370-7.

19.

Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma.

Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M, Tsuneyoshi M.

J Clin Pathol. 2003 Nov;56(11):854-60.

20.

Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha.

Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Nakamura M, Yoshioka S, Kato H, Damdinsuren B, Tang D, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Sakon M, Dono K, Wakasa K, Monden M.

Liver Int. 2006 May;26(4):414-23.

PMID:
16629644

Supplemental Content

Support Center